Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
NCT04061512
Recruiting
Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally. Typically a disease of the elderly, the median age of presentation is \>70 years and the current treatment for WM is unsatisfactory, with incomplete responses and inevitable recurrence. Therefore there is a need to find alternative treatments that are more effective, leading to lasting responses and improved quality of life. The RAINBOW study is a phase 2-3 trial a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Royal United Hospital, Bath, Bath, Not set +24 locations
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
NCT01659658
Terminated
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic light chain (AL) amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +65 locations
Conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
Register for Updates
VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia
NCT02528123
Completed
The purpose of this study is to validate the safety and effectiveness of treating myopia (short-sightedness) higher than -10D using small incision lenticule extraction (SMILE) with the VisuMax femtosecond laser.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/19/2024
Locations: London Vision Clinic, London, Not set
Conditions: Myopia, Refractive Errors
Register for Updates
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
NCT03151811
Terminated
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with RRMM following 2-4 lines of prior therapy and who were refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose of lenalidomide. Patients received either melflufen+dex or pomalidomide+dex.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: US17, Tucson, Arizona +104 locations
Conditions: Multiple Myeloma
Register for Updates
Randomised Evaluation of COVID-19 Therapy
NCT04381936
Recruiting
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) Influenza: Baloxavir marboxil, Oseltamivir, Low-dose corticosteroids... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
01/02/2024
Locations: Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Not set +6 locations
Conditions: Severe Acute Respiratory Syndrome
Register for Updates
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and imp... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
10/17/2023
Locations: Vascular Care Connecticut, Darien, Connecticut +14 locations
Conditions: Iliofemoral; Thrombosis
Register for Updates
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
NCT04524455
Completed
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusion (cIV) blinatumomab.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/11/2023
Locations: City of Hope National Medical Center, Duarte, California +18 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
NCT02755597
Completed
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/18/2023
Locations: Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 156524, Aurora, Colorado +96 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
NCT02592707
Terminated
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas +8 locations
Conditions: Neuroendocrine Tumors
Register for Updates
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
NCT02623426
Completed
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out after 6 months of follow-up. The primary outcome is perce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Jules Stein Eye Institute, UCLA, Los Angeles, California +32 locations
Conditions: Uveitis, Macular Edema
Register for Updates
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT01734928
Completed
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: Southern Cancer Center, Mobile, Alabama +320 locations
Conditions: Multiple Myeloma
Register for Updates
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
NCT03705507
Terminated
This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of acute lymphoblastic leukaemia (ALL) in both adults and children. Phase I is to find the most suitable dose of selumetinib to safely give with dexamethasone. Phase II will use this dose to find out how well the combination works.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2023
Locations: Rigshospitalet, Copenhagen, Not set +16 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Recurrent
Register for Updates